Viemed Healthcare, Inc. (VMD) Price Target Analysis
Analyst Rating: Buy
Based on 1 analystsNo Target Data
VMD trades at Wall Street's consensus target of —.
Current Price$11.63
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E25.6x
(Growth Premium)
PEG Ratio—
Implied Growth+23.7%
(Moderate)
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes VMD achieves its forward estimates and maintains a stable P/E multiple of 25.6x. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
VMD Price Target Analysis
Updated June 29, 2026As of June 29, 2026, Viemed Healthcare, Inc. (VMD) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $446M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, VMD trades at a trailing P/E of 31.4x and forward P/E of 25.6x. Analysts expect EPS to grow +23.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $14.15, with bear and bull scenarios of $8.92 and $18.65 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+26.4%
Industry Consensus
Avg Forward P/E
28.3x
(Growth Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LINCLincoln Educational Services Corporation | $1.6B | $49.89 | $53.80 | +7.8% | Buy | 63.4x | 15 |
 BRTBRT Apartments Corp. | $294M | $15.63 | $21.00 | +34.4% | Buy | — | 5 |
 EHABEnhabit, Inc. | $707M | $13.80 | $13.53 | -2.0% | Hold | 23.0x | 11 |
 HCSGHealthcare Services Group, Inc. | $1.7B | $24.31 | $24.50 | +0.8% | Hold | 22.5x | 15 |
 ADUSAddus HomeCare Corporation | $1.8B | $96.95 | $122.00 | +25.8% | Buy | 13.9x | 16 |
 INSPInspire Medical Systems, Inc. | $1.3B | $45.72 | $56.00 | +22.5% | Hold | 51.0x | 27 |
 NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
 PHGKoninklijke Philips N.V. | $25.8B | $27.10 | — | — | Hold | 17.3x | 22 |
 RMDResMed Inc. | $29.2B | $200.29 | $261.43 | +30.5% | Buy | 18.0x | 35 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
VMD — Frequently Asked Questions
Quick answers to the most common questions about buying VMD stock.
What is the VMD stock price target for 2026?
The consensus price target for VMD is $N/A, close to the current price of $11.63 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
Is VMD a buy, sell, or hold?
VMD has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is VMD stock overvalued or undervalued?
VMD trades at a forward P/E of 25.5604x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.
How high can VMD stock go?
The most bullish Wall Street analyst has a price target of $N/A for VMD, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $19 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover VMD stock?
VMD is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the VMD stock forecast?
The 12-month VMD stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $14, with bear/bull scenarios of $9/$19.
What is VMD's fair value based on fundamentals?
Our quantitative valuation model calculates VMD's fair value at $14 (base case), with a bear case of $9 and bull case of $19. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
What is VMD's forward P/E ratio?
VMD trades at a forward P/E ratio of 25.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy VMD stock?
VMD appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do VMD price targets vary so much?
VMD analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $9-$19 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare